Key takeaways

  • H1 2026 revenue fell to £47.2m from £57.2m a year earlier, but adjusted operating profit rose to £11.5m and margin expanded to 24.3%, aided partly by favourable contract phasing in the CMS2 maritime systems division.
  • Science Group ended the period with cash of roughly £67.9m and net funds of about £56.8m, alongside an active buyback that returned £13.5m to shareholders in H1 2026 and is expected to exceed £20m for the full year.
  • Management flagged early signs of improvement in UK defence contracting following publication of the Defence Investment Plan, while Frontier Smart Technologies continues to navigate soft consumer electronics demand and higher component costs.

Science Group plc (LSE: SAG) rarely makes headlines, yet the Cambridge-based science, engineering and systems group has quietly built one of AIM's more distinctive balance sheets: substantial net cash alongside a long-running buyback. On 27 July 2026 it published interim results for the six months to 30 June 2026. The figures show a familiar pattern: lower headline revenue but improved profitability, against continued caution around UK defence contracting.

Latest company development

The interim results, released 27 July 2026, showed revenue of £47.2m for H1 2026, down from £57.2m, while adjusted operating profit rose to £11.5m from £11.3m and margin improved markedly to 24.3% from 19.7%. Adjusted EPS edged up to 20.4p from 19.3p. Management said trading conditions were 'beginning to improve' after publication of the Defence Investment Plan. The buyback continued through the period, with shares purchased at 583p on 27 July 2026.

Recent financial performance

The interims follow a strong FY2025 (year to 31 December 2025), reported 17 March 2026: revenue £111.7m (2024: £110.7m), adjusted operating profit £23.1m (£21.5m), margin 20.7% (19.5%). Statutory pre-tax profit jumped to £41.5m from £14.7m, reflecting a £24.1m gain on the Ricardo plc investment. The board recommended a final dividend of 10.0p, up 25% on 8.0p, since approved by shareholders. The H1 2026 revenue decline partly reflects lower pass-through defence revenue.

Revenue, earnings, margins and cash flow

By segment, H1 2026 core revenue at Sagentia Services was £28.2m (H1 2025: £29.0m), adjusted operating profit £7.0m (£7.9m), margin stable at 24.0%. CMS2 delivered adjusted operating profit of £4.3m, up from £3.6m, margin jumping to 38.3% from 21.9%, attributed chiefly to contract-delivery timing, so normalisation looks likely later in 2026. Frontier held adjusted operating profit flat at £0.9m on revenue of £6.8m (£7.1m). Operating cash generation was £10.7m, down from a stronger comparator, cash conversion 94%.

Balance sheet and debt

The balance sheet is a defining feature. At 30 June 2026, group cash stood at roughly £67.9m and net funds at about £56.8m, down from an exceptionally high £82.0m and £70.3m a year earlier, a period inflated by Ricardo proceeds since largely returned to shareholders. Debt is modest: two ten-year term loans totalling £12.0m, secured on freehold property, carry a fixed rate of 7.3% via swaps with no covenants, and a £30m revolving facility remains undrawn.

Business model and segments

Science Group operates three businesses. Sagentia Services is a fee-based consultancy delivering R&D projects across MedTech, consumer, food and beverage, defence and industrial markets. CMS2, built from the 2021–2023 acquisition of TP Group for around £30m, designs atmosphere management and life-support systems for submarine programmes, giving long contract cycles tied to naval procurement. Frontier Smart Technologies, acquired in 2019 for roughly £13m, develops DAB/DAB+ digital radio and audio chips, including its Auria product line shipping since April 2026.

Management strategy and growth drivers

Executive chairman Martyn Ratcliffe has controlled Science Group since acquiring a stake in 2010 for around £2.5m, since when revenue and profit have grown substantially. His approach favours disciplined bolt-on acquisitions of underperforming businesses, conservative organic growth, and a focus on margin and cash generation. The board has repeatedly said its small-cap AIM valuation limits capacity for larger M&A, pushing allocation toward dividends and buybacks, alongside occasional opportunistic investing such as the 2025 Ricardo stake-building exercise.

Acquisitions, disposals and restructuring

The largest capital event of the past eighteen months was Science Group's investment in Ricardo plc. Between February and May 2025 the group built a 21.8% stake for roughly £32.7m at 239p average, then exited in June 2025 after a takeover approach, realising proceeds of about £58.2m and a pre-tax gain of £24.1m, over 70% in under five months. No new acquisitions accompanied the H1 2026 results; management describes M&A as under evaluation, alongside freehold property as a source of value.

Industry and macroeconomic context

UK defence has been a swing factor over the past year, with delays tied to deferral of the Defence Investment Plan affecting Sagentia's defence-related consultancy and, less so, CMS2's submarine programmes, seen as more insulated given their multi-decade procurement horizon. Publication of the plan in July 2026 appears to be easing that uncertainty, though contract-award pace remains unconfirmed. Frontier's consumer electronics markets face memory-chip cost inflation and discretionary spending pressure affecting component-dependent suppliers broadly.

Competitive strengths

Science Group's consultancy arm has historically achieved higher revenue per employee than some larger listed peers, reflecting a premium-project client base and lean cost structure. Group-wide adjusted operating margins in the 20–25% range compare favourably with many consultancy peers, with consistently strong cash conversion. The near debt-free balance sheet, undrawn credit facility and absence of restrictive covenants provide flexibility few AIM peers can match, while CMS2's submarine-related work offers revenue visibility into the 2030s.

Material risks and uncertainties

Key risks include volatility in UK defence contracting, which has already driven revenue declines and could recur; the likelihood CMS2's unusually high margin normalises as phasing evens out; and softness in Frontier's consumer markets amid component cost inflation. US dollar revenue is over a quarter of turnover, adding currency exposure, while the AIM listing and small market capitalisation constrain larger acquisitions and tie the business closely to its long-standing chairman and controlling shareholder.

Bull case

Supporters point to disciplined capital allocation, exemplified by the profitable Ricardo trade, alongside strong cash conversion and margins holding up despite revenue swings. Substantial net cash, a significant share of market value, provides optionality for further buybacks, special dividends or selective M&A. CMS2's exposure to long-cycle submarine programmes offers unusually long revenue visibility for a small-cap, and any acceleration in defence contracting after the DIP publication could provide a tailwind into 2027.

Bear case

Sceptics would note reported revenue has declined for two consecutive periods, and H1 2026's improved margin was flattered by CMS2 contract-timing benefits unlikely to repeat at the same scale. Frontier remains exposed to discretionary consumer spending and rising component costs, with limited scale to offset weakness elsewhere. The persistent AIM valuation discount management cites as constraining M&A could equally cap re-rating, leaving the group reliant on cost discipline rather than top-line growth.

What investors may monitor next

Attention will likely turn to the pace of new UK defence contract awards after the Defence Investment Plan's publication, and whether CMS2's margin normalises as signalled. Frontier's Auria product, expected to reach consumer availability in late summer 2026, is a further watchpoint, as is the cadence of buybacks, which management has said could exceed £20m this year. Any fresh M&A commentary, alongside FY2026 preliminary results due in early 2027, would also be relevant.

Outlook

Science Group plc (LSE: SAG) remains an understated but disciplined presence on AIM, combining a cash-generative consultancy and systems business with a conservative, buyback-oriented approach to capital allocation. The H1 2026 results capture both sides of that story: a decline in headline revenue tied largely to defence-sector timing, offset by margin expansion and continued shareholder returns. With defence contracting showing early signs of improvement, coming months should clarify whether recent margin strength can be sustained.